Donepezil Donepezil

X

Find Drugs in Development News & Deals for Donepezil

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 10MG
  • TABLET;ORAL - 5MG
  • TABLET, ORALLY DISINTEGRATING;ORAL - 10MG
  • TABLET, ORALLY DISINTEGRATING;ORAL - 5MG
  • TABLET;ORAL - 23MG

Details:

ADLARITY (donepezil transdermal system) developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type.


Lead Product(s): Donepezil

Therapeutic Area: Neurology Product Name: Adlarity

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval process.


Lead Product(s): Donepezil

Therapeutic Area: Neurology Product Name: Adlarity

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lotus Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.


Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride

Therapeutic Area: Neurology Product Name: SUVN-502

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology.


Lead Product(s): Donepezil,Memantine Hydrochloride

Therapeutic Area: Neurology Product Name: Cognic

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The results of Study 419 did not show statistically significant difference in efficacy between placebo and Aricept (donepezil hydrochloride) groups at time of final analysis in primary endpoint, CIBIC-plus comprehensive assessment.


Lead Product(s): Donepezil

Therapeutic Area: Neurology Product Name: Aricept

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as acetylcholinesterase inhibitors.


Lead Product(s): Donepezil

Therapeutic Area: Neurology Product Name: Adlarity

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content